Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: A randomised trial

Lancet

Volumn 356, Issue 9240, 2000, Pages 1470-1474

  Fitzgerald, Daniel W ^a   Desvarieux, Moïse ^c   Severe, Patrice ^b   Joseph, Patrice ^b   Johnson Jr , Warren D ^a   Pape, Jean William ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PLACEBO;

ACID FAST BACTERIUM; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; FEMALE; HAITI; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS;

EID: 0034727452     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02870-1     Document Type: Article

References (27)

1. Tuberculosis and human immunodeficiency virus infection
2. Treatment of tuberculosis and tuberculosis infection in adults and children
3. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
4. Treatment and prophylaxis of Isospora belli infection in patients with acquired immunodeficiency syndrome
5. Diagnostic standards and classification of tuberculosis
6. Effects of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
7. Classification system for human T-1 lymphocytic virus type III/lymphadenopathy-associated virus infections
8. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
9. A rapid manual method for CD4+ T-cell quantitation for use in developing countries
10. Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya
11. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire
12. The impact of human immunodeficincy virus on response to treatment and recurrence rate in patients treated for tuberculosis: Two-year follow-up of a cohort in Lusaka, Zambia
13. HIV and tuberculosis in rural sub-Saharan Africa: A cohort study with two years follow-up
14. Risk factors for relapse in human immunodeficiency virus type I infected adults with pulmonary tuberculosis
15. Two-year follow-up of persons with HIV-1 and HIV-2 associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa
16. Six month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection
17. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa
18. Pulmonary tuberculosis in HIV-infected patients in Zaire
19. Directly observed therapy and treatment adherence
20. Randomised controlled trial of self supervised and directly observed treatment of tuberculosis
21. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients
22. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration
23. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire
24. Human immunodeficiency virus and the outcome of treatment for new anc recurrent pulmonary tuberculosis in African patients